Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.49 |
| ▸ | SCD | O00767 | 2/20 | 0.47 |
| ▸ | ACACB | O00763 | 2/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16260552 | 0.83 | CYP19A1 (0.50) | CYP11B1CYP11B2CYP19A1ACACBCREBBP | |
| SCHEMBL16343259 | 0.83 | L3MBTL1 (0.57) | L3MBTL1CYP11B1CYP11B2CYP19A1SCD | |
| SCHEMBL3751342 | 0.83 | L3MBTL1 (0.57) | L3MBTL1CYP11B1CYP11B2CYP19A1ACACB | |
| SCHEMBL15123353 | 0.80 | CYP19A1 (0.57) | L3MBTL1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17693908 | 0.80 | CACNA1H (0.46) | CYP11B1CYP11B2CYP19A1ACACBCREBBP | |
| SCHEMBL27225427 | 0.78 | L3MBTL1 (0.56) | L3MBTL1CYP11B1CYP11B2CYP19A1CREBBP | |
| SCHEMBL28397084 | 0.78 | ACACB (0.52) | L3MBTL1CYP11B1CYP11B2CYP19A1SCD | |
| SCHEMBL27374657 | 0.76 | L3MBTL1 (0.57) | L3MBTL1CYP11B1CYP11B2CYP19A1SCD | |
| SCHEMBL10789578 | 0.76 | — | — | |
| SCHEMBL17379604 | 0.74 | SCD (0.50) | L3MBTL1CYP11B1CYP11B2SCDITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7614145-B2 | Method for manufacturing multilayer circuit board and resin base material | ZEON CORPORATION (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| CN-1684944-A | method for copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2005-10-19 | — | — | CN | disclosed |
| US-20050153059-A1 | Partial plating method, partially-plated resin base, method for manufacturing multilayered circuit board | ZEON CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| CN-1639384-A | Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board | ZEON CORP (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1534671-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6888032-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040237295-A1 | Multilayer circuit board and resin base material, and its production method | ZEON CORPORATION (JP) | 2004-12-02 | — | — | US | disclosed |
| CN-1552174-A | Mulitilayer circuit board, resin base material, and its production method | �ձ�������ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-15 | — | — | US | disclosed |
| WO-2004013094-A2 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250959-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | L3MBTL1 2006/4885CYP11B1 1280/4885CYP11B2 897/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | L3MBTL1 3021/4885CYP11B1 3354/4885CYP11B2 3125/4885 |
| US-20040138468-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | CBR3, TST, CBS | L3MBTL1 1910/4885CYP11B1 1260/4885CYP11B2 886/4885 |
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | L3MBTL1 4344/4885CYP11B1 1587/4885CYP11B2 1393/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | L3MBTL1 3021/4885CYP11B1 3354/4885CYP11B2 3125/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | L3MBTL1 2377/4885CYP11B1 2031/4885CYP11B2 1603/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | L3MBTL1 3021/4885CYP11B1 3354/4885CYP11B2 3125/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | L3MBTL1 4344/4885CYP11B1 1587/4885CYP11B2 1393/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | L3MBTL1 3021/4885CYP11B1 3354/4885CYP11B2 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.